-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

180 TARC Predicts PET-Normalization and Event Free Surival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated with Brentuximab Vedotin

Hodgkin Lymphoma: Biology, excluding Therapy
Program: Oral and Poster Abstracts
Type: Oral
Session: 621. Hodgkin Lymphoma: Biology, excluding Therapy: Biological Insights and Clinical Impact
Sunday, December 6, 2015: 8:45 AM
W307, Level 3 (Orange County Convention Center)

Alison J Moskowitz, MD1, Sun Cho2*, Martin Fleisher, PhD2*, Kaitlin M Woo, MS3*, Zhigang Zhang, PhD3*, Stephanie Fox2*, Susan J McCall, MSN ANP-BC2*, Heiko Schoder, MD2*, Joachim Yahalom, MD2* and Craig H Moskowitz, MD4

1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
2Memorial Sloan Kettering Cancer Center, New York, NY
3Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
4Department of Medicine, Lymphoma and Adult BMT Services, Memorial Sloan Kettering Cancer Center, New York, NY

Background/methods: Hodgkin lymphoma (HL) is characterized by elevations in serum cytokines and chemokines, produced by HL Reed-Sternberg cells and surrounding inflammatory cells, several which have been found to be prognostic and/or predictive for response to therapy.  We previously reported the results of our phase II study evaluating PET-adapted salvage therapy with single-agent brentuximab vedotin (BV) followed by augmented ICE for patients with relapsed or refractory (rel/ref) HL (Lancet Oncology 2015).  In this study, patients who failed 1 line of therapy for HL were treated with 2 cycles of BV, 1.2mg/Kg, administered weekly, 3 weeks on and 1 week off.  Those who acheived PET-normalization proceeded directly to consolidation with autologous stem cell transplantation (ASCT).  Those with persistent abnormalities on PET received augmented ICE prior to consideration for ASCT.   Patients with localized, nodal-based disease that had not previously been radiated received involved field radiation prior to ASCT.  Interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and cysteine-cysteine thymus and activation related chemokine (TARC) were measured at baseline and after 2 cycles of BV by multiplex enzyme-linked immunosorbent assay (ELISA) array.  We aimed to evaluate the prognostic and predictive significance of these cytokines and chemokines in this uniformly treated patient population. 

Results: Of the 45 patients enrolled onto this protocol 37 (82%) had serum samples available both at baseline and after 2 cycles of BV for analysis.  Table 1 displays the median values and ranges at baseline and after treatment with BV.  Baseline levels of IL-6, IL-10, TNF-α, IFN-γ, and TARC were abnormal in 32%, 8%, 78%, 97%, and 97%, respectively.  Elevated baseline IFN-γ and IL-10 correlated with presence of extranodal sites of disease (p=0.003 and 0.049 respectively) whereas elevated IL-10 and TNF-α correlated with the presence of B-symptoms (p=0.019 and 0.019 respectively). With regard to response to treatment, percent change in TARC (TARC%) from baseline to post-BV predicted for PET-normalization following BV (OR 5.82, 95% C.I 1.18-43.74).  Furthermore, lower post-BV TARC was significantly associated with improved event free survival (EFS) (2 year EFS 94% vs 67%, p=0.033) (Figure 1).  No other factors correlated with response to therapy, event free survival, or overall survival. 

Conclusions:  To date, this is the largest series evaluating the prognostic and predictive significance of TARC in rel/ref HL patients treated with BV.   Our analysis confirms the role of TARC as a biomarker of response to BV and PET-normalization.  In line with its correlation with PET-normalization, post-BV TARC level was also predictive of EFS.  Continued incorporation of TARC evaluation in prospective clinical trials for HL is warranted to better define its role in predicting PET-normalization and prognosis.

Table 1

Cytokine/chemokine

Pre-brentuximab vedotin (pg/ml)

Post-brentuximab vedotin (pg/ml)

median

range

median

range

IL-6

2.27

0.10-154.44

1.41

0.09-34.00

IL-10

0.38

0.09-112.29

0.45

0.14-17.53

TNF-α

2.55

0.55-15.15

2.25

0.58-22.31

IFN-γ

8.66

1.45-1553.67

9.01

2.62-112.83

TARC

8250.00

236.10-220773.00

1026.70

241.70-34453.00

Figure 1

Disclosures: No relevant conflicts of interest to declare.

<< Previous Abstract | Next Abstract

*signifies non-member of ASH